New study tracks Real-World safety of hATTR-PN drug TEGSEDI
Knowledge-focused
Recruiting now
This study follows 240 adults with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) to monitor the long-term safety of the drug TEGSEDI. Researchers will compare patients who have taken TEGSEDI with those who have not, focusing on risks like low platelet counts…
Sponsor: Akcea Therapeutics • Aim: Knowledge-focused
Last updated May 03, 2026 23:18 UTC